Qian Xinyu, Zhu Lin, Han Na, Qin Jing
Department of Oncology, Hangzhou Cancer Hospital, Hangzhou First People's Hospital, Hangzhou, China.
Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Transl Lung Cancer Res. 2024 Jun 30;13(6):1365-1375. doi: 10.21037/tlcr-24-467. Epub 2024 Jun 27.
Small cell lung cancer (SCLC) is highly malignant and has a higher risk of recurrence even in patients who undergo early surgery. However, a subgroup of patients survived for many years. So far, the factors that determine the long-term survivorship remain largely unknown. To determine the genetic characteristics of long-term survival (LTS) after surgery in SCLC, we performed comprehensive comparative genomic profiling and tumor mutation burden (TMB) analysis of resected tumor tissues from patients with LTS and short-term survival (STS) after surgery.
The present study screened 11 patients from 52 patients with SCLC who underwent surgery at Zhejiang Cancer Hospital from April 2008 to December 2017. A total of six LTS patients (≥4 years) with stage IIB or IIIA SCLC and five STS patients (<2 years) with stage IA or IB SCLC were included in the study. The STS patients were used as a control. All the patients underwent resection without neoadjuvant therapy. We assessed the genomic profiles of the resected tumor tissues and calculated the TMB using next-generation sequencing. We then analyzed and compared the molecular characteristics between the LTS and STS groups.
Our data indicated that tumor tissues from patients with LTS harbor a high TMB. The median TMB for LTS patients was high (approximately 16.4 mutations/Mb), while that for STS patients was low (approximately 8.5 mutations/Mb). The median TMB of patients with LTS and STS showed a trend of significant difference (P=0.08). Gene alterations characterized the survival differences between the two groups. The mutation was only found in the LTS group, and the P value determined by Fisher's exact test was 0.06.
A high non-synonymous TMB and the mutation could potentially influence LTS after SCLC resection. This study provides valuable information about the molecular differences between LTS and STS patients. Studies with larger sample sizes need to be conducted to confirm our findings in the future.
小细胞肺癌(SCLC)具有高度恶性,即使是接受早期手术的患者,复发风险也较高。然而,有一小部分患者存活了多年。迄今为止,决定长期生存的因素在很大程度上仍不清楚。为了确定SCLC手术后长期生存(LTS)的基因特征,我们对手术后LTS和短期生存(STS)患者的切除肿瘤组织进行了全面的比较基因组分析和肿瘤突变负荷(TMB)分析。
本研究从2008年4月至2017年12月在浙江省肿瘤医院接受手术的52例SCLC患者中筛选出11例。研究共纳入6例IIB期或IIIA期SCLC的LTS患者(≥4年)和5例IA期或IB期SCLC的STS患者(<2年)。STS患者作为对照。所有患者均未接受新辅助治疗即进行了手术切除。我们评估了切除肿瘤组织的基因组图谱,并使用二代测序计算TMB。然后我们分析并比较了LTS组和STS组之间的分子特征。
我们的数据表明,LTS患者的肿瘤组织具有较高的TMB。LTS患者的TMB中位数较高(约16.4个突变/Mb),而STS患者的TMB中位数较低(约8.5个突变/Mb)。LTS和STS患者的TMB中位数显示出显著差异的趋势(P = 0.08)。基因改变是两组生存差异的特征。该突变仅在LTS组中发现,Fisher精确检验确定的P值为0.06。
高非同义TMB和该突变可能会影响SCLC切除术后的LTS。本研究提供了关于LTS和STS患者分子差异的有价值信息。未来需要进行更大样本量的研究来证实我们的发现。